Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacob Schachter

Showing results (141-150 of 153) with videos related to

Pageof 16
Sort By:
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
The New England Journal of Medicine|November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinibCaroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Cell|September 10, 2019
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial DependenceMichal Harel, Rona Ortenberg, Siva Karthik Varanasi, et al.
The New England Journal of Medicine|June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaCaroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Oncoimmunology|July 4, 2012
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patientsPia Kvistborg, Chengyi Jenny Shu, Bianca Heemskerk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.
Science (New York, N.Y.)|December 11, 2020
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patientsErez N Baruch, Ilan Youngster, Guy Ben-Betzalel, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Pageof 16

Showing results (141-150 of 153) with videos related to

Sort By:
Pageof 16
The Lancet. Oncology|October 5, 2015
Comparison of dabrafenib and trametinib combination therapy with vemurafenib monotherapy on health-related quality of life in patients with unresectable or metastatic cutaneous BRAF Val600-mutation-positive melanoma (COMBI-v): results of a phase 3, open-label, randomised trialJean Jacques Grob, Mayur M Amonkar, Boguslawa Karaszewska, et al.
The New England Journal of Medicine|November 18, 2014
Improved overall survival in melanoma with combined dabrafenib and trametinibCaroline Robert, Boguslawa Karaszewska, Jacob Schachter, et al.
European Journal of Cancer (Oxford, England : 1990)|December 28, 2020
Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: A landmark analysis in patients with advanced melanomaCaroline Robert, Wen-Jen Hwu, Omid Hamid, et al.
European Journal of Cancer (Oxford, England : 1990)|June 27, 2017
Three-year pooled analysis of factors associated with clinical outcomes across dabrafenib and trametinib combination therapy phase 3 randomised trialsDirk Schadendorf, Georgina V Long, Daniil Stroiakovski, et al.
Cell|September 10, 2019
Proteomics of Melanoma Response to Immunotherapy Reveals Mitochondrial DependenceMichal Harel, Rona Ortenberg, Siva Karthik Varanasi, et al.
The New England Journal of Medicine|June 6, 2019
Five-Year Outcomes with Dabrafenib plus Trametinib in Metastatic MelanomaCaroline Robert, Jean J Grob, Daniil Stroyakovskiy, et al.
Oncoimmunology|July 4, 2012
TIL therapy broadens the tumor-reactive CD8(+) T cell compartment in melanoma patientsPia Kvistborg, Chengyi Jenny Shu, Bianca Heemskerk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 13, 2018
Selumetinib in Combination With Dacarbazine in Patients With Metastatic Uveal Melanoma: A Phase III, Multicenter, Randomized Trial (SUMIT)Richard D Carvajal, Sophie Piperno-Neumann, Ellen Kapiteijn, et al.
Science (New York, N.Y.)|December 11, 2020
Fecal microbiota transplant promotes response in immunotherapy-refractory melanoma patientsErez N Baruch, Ilan Youngster, Guy Ben-Betzalel, et al.
The Lancet. Oncology|June 28, 2015
Pembrolizumab versus investigator-choice chemotherapy for ipilimumab-refractory melanoma (KEYNOTE-002): a randomised, controlled, phase 2 trialAntoni Ribas, Igor Puzanov, Reinhard Dummer, et al.
Pageof 16